Education
About Us
Working with TipRanks
Follow Us
Perspective Therapeutics (CATX)
:CATX
RESEARCH TOOLSreports
CATX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.36 - $19.05
Previous CloseN/A
Volume311.62K
Average Volume (3M)772.24K
Market Cap
$187.89M
Enterprise Value$679.32M
Total Cash (Recent Filing)$3.20M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.13
Next Earnings
Mar 26, 2025EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.93
Shares Outstanding67,587,540
10 Day Avg. Volume614,792
30 Day Avg. Volume772,243
Standard Deviation0.46
R-Squared0.02
Alpha0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)143.42
Price to Cash Flow (P/CF)13.10
P/FCF Ratio0.00
Enterprise Value/Market Cap3.62
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit473.72
Enterprise Value/Ebitda-15.07
Forecast
1Y Price Target
$15.80Price Target Upside468.35% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
---
Perspective Therapeutics News
---
Bulls Say, Bears Say
Bulls Say
Financial PositionCATX reported a preliminary estimated unaudited cash position of approximately $227.8 million, which is expected to fund operations into late 2026.
Safety And TolerabilityThe safety profile has continued to look strong, with no DLTs, minimal grade 3+ TEAEs, and no decline in renal function.
Bears Say
Efficacy ConcernsThe significant negative stock reaction was in response to perceptions that the efficacy fell short of the high expectations that were established with the asset's performance in the investigator initiated trial in India.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
CATX FAQ
What was Perspective Therapeutics’s price range in the past 12 months?
Perspective Therapeutics lowest stock price was $2.36 and its highest was $19.05 in the past 12 months.
What is Perspective Therapeutics’s market cap?
Perspective Therapeutics’s market cap is $187.89M.
When is Perspective Therapeutics’s upcoming earnings report date?
Perspective Therapeutics’s upcoming earnings report date is Mar 26, 2025 which is in 23 days.
How were Perspective Therapeutics’s earnings last quarter?
Perspective Therapeutics released its earnings results on Nov 12, 2024. The company reported -$0.21 earnings per share for the quarter, beating the consensus estimate of -$0.213 by $0.003.
Is Perspective Therapeutics overvalued?
According to Wall Street analysts Perspective Therapeutics’s price is currently Undervalued.
Does Perspective Therapeutics pay dividends?
Perspective Therapeutics does not currently pay dividends.
What is Perspective Therapeutics’s EPS estimate?
Perspective Therapeutics’s EPS estimate is -0.27.
How many shares outstanding does Perspective Therapeutics have?
Perspective Therapeutics has 67,587,540 shares outstanding.
What happened to Perspective Therapeutics’s price movement after its last earnings report?
Perspective Therapeutics reported an EPS of -$0.21 in its last earnings report, beating expectations of -$0.213. Following the earnings report the stock price went down -6.935%.
Which hedge fund is a major shareholder of Perspective Therapeutics?
Currently, no hedge funds are holding shares in CATX
---
Perspective Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.80 (468.35% Upside)
$15.80 (468.35% Upside)
Blogger Sentiment
Bullish
CATX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 1.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $130.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 6.9%
Last 30 Days ▼ 6.9%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-69.11%
12-Months-Change
Fundamentals
Return on Equity
-19.42%
Trailing 12-Months
Asset Growth
253.93%
Trailing 12-Months
Company Description
Perspective Therapeutics
IsoRay, Inc. is a medical technology company, which engages in the development, manufacture, and sale of isotope-based medical products and devices. The company focuses on the treatment of cancer and other malignant diseases. Its core product is Cesium-131, a radioisotope for the treatment of malignant tumors. The company was founded by Lance A. Bray in 1983 and is headquartered in Richland, WA.
---
CATX Stock 12 Month Forecast
Average Price Target
$15.80
▲(468.35% Upside)
Technical Analysis
Organovo Holdings
―
Sorrento Therapeutics
―
TG Therapeutics
―
Fennec Pharmaceuticals
―
ADC Therapeutics
―
Best Analysts Covering CATX
1 Year
1 Year Success Rate
4/13 ratings generated profit
1 Year Average Return
+4.13%
reiterated a buy rating last month
Copying Jeff Jones's trades and holding each position for 1 Year would result in 30.77% of your transactions generating a profit, with an average return of +4.13% per trade.
---